 Outlook Therapeutics intends to market ONS-5010 as LYTENAVATM bevacizumab-vikg, if approved. LYTENAVATM bevacizumab-vikg, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two registration clinical trials NORSE 1 and NORSE 2 to treat wet age-related macular degeneration wet AMD. CRANBURY, N.J., March 05, 2020 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has received U.S. Food and Drug Administration FDA tentative approval of the Tradename for ONS-5010 as LYTENAVATM bevacizumab-vikg. 